Illegal Use of Testosterone and Other Anabolic–Androgenic Steroids in the Population of Amateur Athletes in Wrocław, Poland—An Unfavorable Lifestyle Trend in the Population of Men of Reproductive Age
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.1.1. Method Used
2.1.2. Recruitment of Respondents
2.1.3. Admission Criteria
2.2. The Questionnaire Structure
2.3. Statistical Analysis
3. Results
3.1. Socio-Demographic Information, Data on Training Habits, and Competition Participation
3.1.1. Age
3.1.2. Education
3.1.3. Economic Status
3.1.4. Employment
3.1.5. Marital Status
3.1.6. Sexual Orientation
3.1.7. Domicile
3.1.8. Length of Training Experience
3.1.9. Frequency of Training
3.1.10. Participation in Weightlifting Competitions
3.1.11. Participation in Bodybuilding Competitions
3.1.12. Having Children
3.1.13. Planning to Have Children
3.2. Data Regarding Testosterone Users
3.2.1. Use of Testosterone or Other Anabolic–Androgenic Steroids
3.2.2. Purpose of Using Testosterone or Other Anabolic–Androgenic Steroids
3.2.3. Use of Other Substances
3.2.4. Purpose of Using Other Substances
3.2.5. What Prompted the Respondents to Use Testosterone or Other Anabolic–Androgenic Steroids?
3.2.6. Sources of Knowledge about Testosterone and Other Anabolic–Androgenic Steroids
3.2.7. Medical Consultations Regarding the Use of Testosterone and Other Anabolic–Androgenic Steroids
3.2.8. Purpose of Medical Consultations Regarding the Use of Testosterone and Other Anabolic–Androgenic Steroids
3.2.9. Performing Laboratory Tests in Connection with the Use of Testosterone and Other Anabolic–Androgenic Steroids
3.2.10. Type of Laboratory Test Performed in Connection with the Use of Testosterone and Other Anabolic–Androgenic Steroids
3.2.11. Knowledge about the Complications of Using Testosterone and Other Anabolic–Androgenic Steroids
3.3. Data Regarding People Not Using Testosterone
3.3.1. Planning to Use Anabolic–Androgenic Steroids
3.3.2. Considering the Use of Anabolic–Androgenic Steroids in the Future
3.3.3. Being Encouraged to Use Anabolic–Androgenic Steroids
3.3.4. Persons Encouraging the Use of Anabolic–Androgenic Steroids
3.3.5. Factors That Influenced Decisions to Not Use Anabolic–Androgenic Steroids
3.4. The Association between Socio-Demographic Data and Using Testosterone
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Levine, H.; Jørgensen, N.; Martino-Andrade, A.; Mendiola, J.; Weksler-Derri, D.; Mindlis, I.; Pinotti, R.; Swan, S.H. Temporal trends in sperm count: A systematic review and meta-regression analysis. Hum. Reprod. Update 2017, 23, 626–659. [Google Scholar] [CrossRef]
- Agarwal, A.; Mulgund, A.; Hamada, A.; Chyatte, M.R. A unique view on male infertility around the globe. Reprod. Biol. Endocrinol. 2015, 13, 37. [Google Scholar] [CrossRef] [PubMed]
- Sellke, N.; Omil-Lima, D.; Sun, H.H.; Tay, K.; Rhodes, S.; Loeb, A.; Thirumavalavan, N. Trends in testosterone prescription during the release of society guidelines. Int. J. Impot. Res. 2024, 36, 380–384. [Google Scholar] [CrossRef] [PubMed]
- Smit, D.L.; de Hon, O.; Venhuis, B.J.; den Heijer, M.; de Ronde, W. Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids. Scand. J. Med. Sci. Sports 2020, 30, 531–539. [Google Scholar] [CrossRef] [PubMed]
- de Ronde, W.; Smit, D.L. Anabolic androgenic steroid abuse in young males. Endocr. Connect. 2020, 9, R102–R111. [Google Scholar] [CrossRef] [PubMed]
- McCabe, S.E.; Brower, K.J.; West, B.T.; Nelson, T.F.; Wechsler, H. Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys. Drug Alcohol Depend. 2007, 90, 243–251. [Google Scholar] [CrossRef] [PubMed]
- Sagoe, D.; Molde, H.; Andreassen, C.S.; Torsheim, T.; Pallesen, S. The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis. Ann. Epidemiol. 2014, 24, 383–398. [Google Scholar] [CrossRef] [PubMed]
- Buckley, W.E.; Yesalis, C.E.; Freidl, K.E.; Anderson, W.A.; Streit, A.L.; Wright, J.E. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988, 260, 3441–3445. [Google Scholar] [CrossRef] [PubMed]
- Lambert, M.I.; Titlestad, S.D.; Schwellnus, M.P. Prevalence of androgenic-anabolic steroid use in adolescents in two regions of South Africa. S. Afr. Med. J. 1998, 88, 876–880. [Google Scholar]
- Handelsman, D.J.; Gupta, L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int. J. Androl. 1997, 20, 159–164. [Google Scholar] [CrossRef]
- Montuori, P.; Loperto, I.; Paolo, C.; Castrianni, D.; Nubi, R.; De Rosa, E.; Palladino, R.; Triassi, M. Bodybuilding, dietary supplements and hormones use: Behaviour and determinant analysis in young bodybuilders. BMC Sports Sci. Med. Rehabil. 2021, 13, 147. [Google Scholar] [CrossRef] [PubMed]
- Handelsman, D.J. Androgen Physiology, Pharmacology, Use and Misuse. In Endotext; MDText.com, Inc.: Dartmouth, MA, USA, 2020. [Google Scholar]
- Mason, K.A.; Schoelwer, M.J.; Rogol, A.D. Androgens During Infancy, Childhood, and Adolescence: Physiology and Use in Clinical Practice. Endocr. Rev. 2020, 41, bnaa003. [Google Scholar] [CrossRef] [PubMed]
- Zitzmann, M. Testosterone, mood, behaviour and quality of life. Andrology 2020, 8, 1598–1605. [Google Scholar] [CrossRef] [PubMed]
- Chrostowski, K.; Kwiatkowska, D.; Pokrywka, A.; Stańczyk, D.; Wójcikowska-Wójcik, B.; Grucza, R. Renin-angiotensin-aldosterone system in bodybuilders using supraphysiological doses of anabolic-androgenic steroids. Biol. Sport 2011, 28, 11–17. [Google Scholar] [CrossRef]
- Feinberg, M.J.; Lumia, A.R.; McGinnis, M.Y. The effect of anabolic-androgenic steroids on sexual behavior and reproductive tissues in male rats. Physiol. Behav. 1997, 62, 23–30. [Google Scholar] [CrossRef] [PubMed]
- Nagata, S.; Kurosawa, M.; Mima, K.; Nambo, Y.; Fujii, Y.; Watanabe, G.; Taya, K. Effects of anabolic steroid (19-nortestosterone) on the secretion of testicular hormones in the stallion. J. Reprod. Fertil. 1999, 115, 373–379. [Google Scholar] [CrossRef] [PubMed]
- Grokett, B.H.; Ahmad, N.; Warren, D.W. The effects of an anabolic steroid (oxandrolone) on reproductive development in the male rat. Acta Endocrinol. 1992, 126, 173–178. [Google Scholar] [CrossRef] [PubMed]
- Shokri, S.; Aitken, R.J.; Abdolvahhabi, M.; Abolhasani, F.; Ghasemi, F.M.; Kashani, I.; Ejtemaeimehr, S.; Ahmadian, S.; Minaei, B.; Naraghi, M.A.; et al. Exercise and supraphysiological dose of nandrolone decanoate increase apoptosis in spermatogenic cells. Basic Clin. Pharmacol. Toxicol. 2010, 106, 324–330. [Google Scholar] [CrossRef] [PubMed]
- Moretti, E.; Collodel, G.; La Marca, A.; Piomboni, P.; Scapigliati, G.; Baccetti, B. Structural sperm and aneuploidies studies in a case of spermatogenesis recovery after the use of androgenic anabolic steroids. J. Assist. Reprod. Genet. 2007, 24, 195–198. [Google Scholar] [CrossRef]
- Al Hashimi, M. The deleterious effects of anabolic androgenic steroid abuse on sexual and reproductive health and comparison of recovery between treated and untreated patients: Single-center prospective randomized study. Andrologia 2022, 54, e14576. [Google Scholar] [CrossRef]
- Neil, D.; Clark, R.V.; Magee, M.; Billiard, J.; Chan, A.; Xue, Z.; Russell, A. GSK2881078, a SARM, produces dose-dependent increases in lean mass in healthy older men and women. J. Clin. Endocrinol. Metab. 2018, 103, 3215–3224. [Google Scholar] [CrossRef] [PubMed]
- Koller, T.; Vrbova, P.; Meciarova, I.; Molcan, P.; Smitka, M.; Adamcova Selcanova, S.; Skladany, L. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J. Clin. Cases 2021, 9, 4062–4071. [Google Scholar] [CrossRef]
- Flores, J.E.; Chitturi, S.; Walker, S. Drug-Induced Liver Injury by Selective Androgenic Receptor Modulators. Hepatol. Commun. 2020, 4, 450–452. [Google Scholar] [CrossRef] [PubMed]
- Hardt, A.; Stippel, D.; Odenthal, M.; Hölscher, A.H.; Dienes, H.P.; Drebber, U. Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: A case report. Case Rep. Pathol. 2012, 2012, 195607. [Google Scholar] [CrossRef]
- Socas, L.; Zumbado, M.; Pérez-Luzardo, O.; Ramos, A.; Pérez, C.; Hernández, J.R.; Boada, L.D. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: A report of two cases and a review of the literature. Br. J. Sports Med. 2005, 39, e27. [Google Scholar] [CrossRef]
- Martin, N.M.; Abu Dayyeh, B.K.; Chung, R.T. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J. Gastroenterol. 2008, 14, 4573–4575. [Google Scholar] [CrossRef]
- Roşca, A.E.; Vlădăreanu, A.M.; Mititelu, A.; Popescu, B.O.; Badiu, C.; Căruntu, C.; Voiculescu, S.E.; Onisâi, M.; Gologan, Ş.; Mirica, R.; et al. Effects of Exogenous Androgens on Platelet Activity and Their Thrombogenic Potential in Supraphysiological Administration: A Literature Review. J. Clin. Med. 2021, 10, 147. [Google Scholar] [CrossRef] [PubMed]
- Henrion, R.; Mandelbrot, L.; Delfieu, D. HIV contamination after injections of anabolic steroids. Presse Med. 1992, 21, 218. [Google Scholar]
- Rich, J.D.; Dickinson, B.P.; Merriman, N.A.; Flanigan, T.P. Hepatitis C virus infection related to anabolic-androgenic steroid injection in a recreational weight lifter. Am. J. Gastroenterol. 1998, 93, 1598. [Google Scholar] [CrossRef]
- Benjamin, A.; Anderson, A.; Zrelec, S. Delayed rhabdomyolysis secondary to anabolic-androgenic steroid use. Clin. Med. (Lond.) 2020, 20, e260–e261. [Google Scholar] [CrossRef]
- Lepori, M.; Perren, A.; Gallino, A. The Popliteal-Artery Entrapment Syndrome in a Patient Using Anabolic Steroids. N. Engl. J. Med. 2002, 346, 1254–1255. [Google Scholar] [CrossRef] [PubMed]
- Kanayama, G.; Hudson, J.I.; Pope, H.G., Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? Drug Alcohol Depend. 2008, 98, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Isaacs, J.T. Resolving the Coffey Paradox: What does the androgen receptor do in normal vs. malignant prostate epithelial cells? Am. J. Clin. Exp. Urol. 2018, 6, 55–61. [Google Scholar] [PubMed]
- Demidenko, E. Sample size determination for logistic regression revisited. Stat. Med. 2007, 26, 3385–3397. [Google Scholar] [CrossRef] [PubMed]
- Alsaeed, I.; Alabkal, J.R. Usage and perceptions of anabolic-androgenic steroids among male fitness centre attendees in Kuwait—A cross-sectional study. Subst. Abuse Treat. Prev. Policy 2015, 10, 33. [Google Scholar] [CrossRef] [PubMed]
- Alshammari, S.A.; AlShowair, M.A.; AlRuhaim, A. Use of hormones and nutritional supplements among gyms’ attendees in Riyadh. J. Family Community Med. 2017, 24, 6–12. [Google Scholar] [CrossRef] [PubMed]
- Angoorani, H.; Halabchi, F. The Misuse of Anabolic-Androgenic Steroids among Iranian Recreational Male Body-Builders and Their Related Psycho-Socio-Demographic factors. Iran. J. Public Health 2015, 44, 1662–1669. [Google Scholar] [PubMed]
- Al-Falasi, O.; Al-Dahmani, K.; Al-Eisaei, K.; Al-Ameri, S.; Al-Maskari, F.; Nagelkerke, N.; Schneider, J. Knowledge, Attitude and Practice of Anabolic Steroids Use Among Gym Users in Al-Ain District, United Arab Emirates. Open Sports Med. J. 2008, 2, 75–81. [Google Scholar] [CrossRef]
- Al Hashimi, M.; Farahat, Y.; Kandil, H.; Al Khalidi, I. Androgenic-anabolic steroid abuse trend and management: A prospective, cross-sectional, questionnaire-based survey. Health Sci. Rep. 2023, 6, e1032. [Google Scholar] [CrossRef]
Variable | Levels | All Population (N = 179) | Study Group (N = 63) | Control Group (N = 116) |
---|---|---|---|---|
Age | 18–25 years old | 49.72 | 33.33 | 58.62 |
26–30 years old | 26.26 | 33.33 | 22.41 | |
31–35 years old | 8.94 | 12.70 | 6.90 | |
36–40 years old | 7.82 | 11.11 | 6.03 | |
41–45 years old | 3.91 | 4.76 | 3.45 | |
46–50 years old | 2.79 | 4.76 | 1.72 | |
51–55 years old | 0.00 | 0.00 | 0.00 | |
56–60 years old | 0.56 | 0.00 | 0.86 | |
Education | Higher education (PhD or higher) | 1.68 | 1.59 | 1.72 |
Higher education | 49.16 | 41.27 | 53.45 | |
Secondary education | 45.25 | 52.38 | 41.38 | |
Vocational education | 1.68 | 3.17 | 0.86 | |
Primary education | 2.23 | 1.59 | 2.59 | |
Earnings | Earnings above PLN 9404 gross/month | 25.14 | 34.92 | 19.83 |
Earnings PLN 3526.50 gross to PLN 9404 gross/month | 46.37 | 50.79 | 43.97 | |
Earnings below PLN 3526.50 gross | 13.41 | 7.94 | 16.38 | |
No income | 15.08 | 6.35 | 19.83 | |
Occupation | Students | 24.58 | 7.94 | 33.62 |
People running their own business | 17.88 | 25.40 | 13.79 | |
Corporate employees | 16.76 | 15.87 | 17.24 | |
Employees of small- and medium-sized enterprises | 13.41 | 12.70 | 13.79 | |
Managers in corporations and enterprises | 7.26 | 14.29 | 3.45 | |
Health care workers | 6.70 | 3.17 | 8.62 | |
Civil servants | 4.47 | 4.76 | 4.31 | |
Unemployed | 2.79 | 3.17 | 2.59 | |
Other | 2.23 | 6.35 | 0.00 | |
Coaches | 1.12 | 1.59 | 0.86 | |
Engineers | 1.12 | 3.17 | 0.00 | |
Uniformed services | 1.12 | 1.59 | 0.86 | |
Athletes | 0.56 | 0.00 | 0.86 | |
Marital status | Married | 15.08 | 22.22 | 11.21 |
In a permanent partnership | 44.69 | 46.03 | 43.97 | |
Single—not in a permanent relationship | 40.22 | 31.75 | 44.83 | |
Sexual orientation | Heterosexual | 96.09 | 96.83 | 95.69 |
Homosexual | 2.79 | 3.17 | 2.59 | |
Bisexual | 0.56 | 0.00 | 0.86 | |
Other | 0.56 | 0.00 | 0.86 | |
Domicile | Village | 8.38 | 9.52 | 7.76 |
City up to 50 thousand inhabitants | 10.61 | 15.87 | 7.76 | |
City up to 100 thousand inhabitants | 8.94 | 14.29 | 6.03 | |
City up to 250 thousand inhabitants | 3.91 | 6.35 | 2.59 | |
City over 250 thousand inhabitants | 68.16 | 53.97 | 75.86 | |
Length of training experience | >24 months | 79.89 | 93.65 | 72.41 |
12–24 months | 6.15 | 3.17 | 7.76 | |
6–12 months | 7.26 | 3.17 | 6.48 | |
3–6 months | 3.35 | 0.00 | 5.17 | |
<3 months | 3.35 | 0.00 | 5.17 | |
Frequency of training | 5–7 times a week | 8.38 | 12.70 | 6.03 |
3–5 times a week | 55.31 | 68.25 | 48.28 | |
2–3 times a week | 30.17 | 19.05 | 36.21 | |
Once a week | 2.79 | 0.00 | 4.31 | |
A few times a month | 2.79 | 0.00 | 4.31 | |
Less than a few times a month | 0.56 | 0.00 | 0.86 | |
Participation in weightlifting competitions | No | 77.65 | 66.67 | 83.62 |
Yes | 22.35 | 33.33 | 16.38 | |
Participation in bodybuilding competitions | No | 96.65 | 90.48 | 100.00 |
Yes | 3.35 | 9.52 | 0.00 | |
Having children | No | 83.80 | 76.19 | 87.93 |
Yes | 16.20 | 23.81 | 12.07 | |
Planning to have children | No | 40.78 | 47.62 | 37.07 |
Yes | 59.22 | 52.38 | 62.93 |
Variable | Levels | Frequency % (k) |
---|---|---|
Testosterone use | No | 64.80 (116) |
(N = 179) | Yes | 35.20 (63) |
Testosterone use period (n = 63) | <1 month | 1.59 (1) |
1–3 months | 14.29 (9) | |
3–6 months | 22.22 (14) | |
6–12 months | 11.11 (7) | |
>12 months | 50.79 (32) | |
Purpose of using testosterone and other anabolic–androgenic steroids (n = 63) | Improving training effects | 87.3 (55) |
Improving resistance to heavy training | 60.32 (38) | |
Improving body shape | 60.32 (38) | |
Improving well-being | 44.44 (28) | |
Improving libido | 25.4 (16) | |
Supplementation of testosterone deficiency | 3.17 (2) | |
Improving sleep and regeneration | 1.59 (1) | |
Body weight reduction | 1.59 (1) | |
All of the above and improved health | 1.59 (1) | |
Improving results in competitions | 1.59 (1) | |
Concomitant use of other anabolic–androgenic steroids (n = 62) | No | 22.58 (14) |
Yes | 77.42 (48) | |
Substances used simultaneously with testosterone (n = 48) | Selective estrogen receptor modulators | 75 (36) |
Aromatase inhibitors | 56.25 (27) | |
Gonadotropins | 47.92 (23) | |
Stimulants | 47.92 (23) | |
Hormones | 35.42 (17) | |
Anabolic–androgenic steroids | 31.25 (15) | |
Other | 12.5 (6) | |
Dietary supplements | 6.25 (3) | |
Dopamine agonist | 6.25 (3) | |
Selective androgen receptor modulators | 6.25 (3) | |
Reason for simultaneous use of other substances (n = 48) | Enhancing the effects of testosterone | 95.83 (46) |
Reducing the side effects of testosterone | 68.75 (33) | |
Increasing only lean body mass | 31.25 (15) | |
Reducing estradiol levels | 4.17 (2) | |
Reducing prolactin levels | 2.08 (1) | |
Improving well-being | 2.08 (1) | |
Counteraction of testicular atrophy | 2.08 (1) | |
Normalization of hormonal test results | 2.08 (1) | |
Improving body shape | 2.08 (1) | |
Increasing strength and efficiency | 2.08 (1) | |
What prompted respondents to use testosterone and other anabolic–androgenic steroids (n = 60) | Friends | 43.33 (26) |
Internet | 35 (21) | |
Publications | 31.67 (19) | |
Personal coach | 18.33 (11) | |
Own decision | 5 (3) | |
Lack of improvement in training effects without anabolic–androgenic steroids | 3.33 (2) | |
A wish to improve recovery after exercise | ||
Low testosterone level | 3.33 (2) | |
Family doctor | 3.33 (2) | |
Sports doctor | 1.67 (1) | |
A wish to move to a higher training level | 1.67 (1) | |
Bad mood | 1.67 (1) | |
A wish to try testosterone and other | 1.67 (1) | |
anabolic–androgenic steroids | 1.67 (1) | |
out | ||
A wish to do sports professionally | 1.67 (1) | |
Knowledge | 1.67 (1) | |
Ambition | 1.67 (1) | |
Source of knowledge about testosterone (n = 63) | Internet | 76.19 (48) |
Publications | 66.67 (42) | |
Friends | 38.1 (24) | |
Personal coach | 31.75 (20) | |
Doctor | 3.17 (2) | |
Own experience | 1.59 (1) | |
Scientific investigation | 1.59 (1) | |
Scientific information on the Internet | 1.59 (1) | |
Podcasts | 1.59 (1) | |
Medical consultation regarding the use of testosterone and anabolic–androgenic steroids (n = 62) | No | 61.29 (38) |
Yes | 38.71 (24) | |
Purpose of medical consultation (n = 27) | To obtain a referral for check-up tests | 66.67 (18) |
Discussion of side effects | 44.44 (12) | |
Discussion of side effects associated with the use of testosterone/other anabolic–androgenic steroids | 44.44 (12) | |
To obtain a prescription for testosterone or other medications | 25.93 (7) | |
To obtain medical advice regarding the duration of use of testosterone/other anabolic–androgenic steroids | 18.52 (5) | |
Assessment of the risk of low testosterone levels | 18.52 (5) | |
Dosage advice | 18.52 (5) | |
Performing laboratory tests in connection with the use of testosterone and other anabolic–androgenic steroids (n = 61) | No | 4.92 (3) |
Yes | 95.08 (58) | |
Type of laboratory test (n = 59) | Blood count | 91.53 (54) |
Estradiol | 86.44 (51) | |
TSH | 84.75 (50) | |
Liver tests | 81.36 (48) | |
Total testosterone | 81.36 (48) | |
Free testosterone | 79.66 (47) | |
Lipid profile | 72.88 (43) | |
Thyroid | 71.19 (42) | |
Free triiodothyronine | 71.19 (42) | |
Free thyroxine | 71.19 (42) | |
SHBG | 52.54 (31) | |
Fasting glucose | 44.07 (26) | |
Fasting insulin | 25.42 (15) | |
DHEA-S | 23.73 (14) | |
Awareness of possible side effects of the use of testosterone and other anabolic–androgenic steroids (n = 62) | Reduction in the size of testicles | 87.1 (54) |
Infertility | 83.87 (52) | |
Hypertension | 83.87 (52) | |
Breast enlargement | 74.19 (46) | |
Changes in blood count | 70.97 (44) | |
Prostatic hyperplasia | 69.35 (43) | |
Liver damage | 66.13 (41) | |
Thrombosis | 50 (31) | |
46.77 (29) |
Variable | Levels | Frequency % (k) |
---|---|---|
Planning to use of anabolic–androgenic steroids (N = 115) | No | 48.70 (56) |
Yes | 51.30 (59) | |
Being encouraged to use anabolic–androgenic steroids (N = 116) | No | 62.07 (72) |
Yes | 37.93 (44) | |
Persons encouraging the use of anabolic–androgenic steroids (N = 44) | Friends from the gym/sports club | 77.27 (34) |
Social groups–Internet | 18.18 (8) | |
Personal coach | 2.27 (1) | |
Partner | 2.27 (1) | |
Factors that influenced decisions not to use anabolic–androgenic steroids (N = 114) | Lack of need | 49.12 (46) |
Fear of side effects | 40.35 (29) | |
Confidence in one’s own capabilities | 5.26 (27) | |
Too young age | 1.39 (1) | |
Beliefs | 0.88 (1) | |
Partner | 0.88 (1) | |
Lack of availability | 0.88 (1) | |
Fear of detection of the use of these substances during sports competitions | 0.88 (1) | |
Considering the use of anabolic–androgenic steroids in the future (N = 115) | No | 46.09 (53) |
Maybe | 22.61 (26) | |
Yes | 31.30 (36) |
Variable | Levels | OR | 95% CL | p-Value |
---|---|---|---|---|
Age | 18–25 years old (ref.) | - | - | - |
26–30 years old | 2.62 | 1.23–5.56 | 0.013 | |
31–35 years old | 3.24 | 1.08–9.68 | 0.036 | |
36–40 years old | 3.24 | 1.02–10.29 | 0.046 | |
41–45 years old | 2.43 | 0.5–11.73 | 0.269 | |
46–50 years old | 4.86 | 0.76–31.04 | 0.095 | |
56–60 years old | 0.00 | 0–0 | 0.998 | |
Education | Higher education (PhD or higher) | 1.50 | 0.06–40.64 | 0.810 |
Higher education | 1.26 | 0.12–12.66 | 0.845 | |
Secondary education | 02.06 | 0.21–20.7 | 0.538 | |
Vocational education | 6.00 | 0.22–162.54 | 0.287 | |
Primary education (ref.) | - | - | - | |
Earnings | Earnings above PLN 9404 gross/month | 5.50 | 1.64–18.48 | 0.006 |
Earnings PLN 3526.50 gross to PLN 9404 gross/month. | 3.61 | 1.14–11.4 | 0.029 | |
Earnings below PLN 3526.50 gross | 1.51 | 0.36–6.44 | 0.575 | |
No income (ref.) | - | - | - | |
Marital status | Married | 2.80 | 1.12–6.99 | 0.027 |
In a permanent partnership | 1.48 | 0.74–2.94 | 0.266 | |
Single–not in a permanent relationship (ref.) | - | - | - | |
Sexual orientation | Heterosexual | 0.82 | 0.13–5.07 | 0.835 |
Homosexual (ref.) | - | - | - | |
Bisexual | 0.00 | 0–0 | 0.998 | |
Other | 0.00 | 0–0 | 0.998 | |
Domicile | Village (ref.) | - | - | - |
City up to 50 thousand inhabitants | 1.67 | 0.42–6.56 | 0.465 | |
City up to 100 thousand inhabitants | 1.93 | 0.46–8.05 | 0.368 | |
City up to 250 thousand inhabitants | 2.00 | 0.32–12.33 | 0.455 | |
City with over 250 thousand inhabitants | 0.58 | 0.19–1.75 | 0.334 | |
Length of training experience | >24 months | 2.81 × 106 | 0–0 | 0.000 |
12–24 months | 8.90 × 105 | 1.86 × 105–4.27 × 106 | 0.000 | |
6–12 months | 7.28 × 105 | 1.56 × 105–3.41 × 106 | 0.000 | |
3–6 months | 0.02 | 0–0 | 0.999 | |
<3 months (ref.) | - | - | - | |
Frequency of training | 5–7 Times A Week | 3.38 × 107 | 1.02 × 107–1.12 × 108 | 0.000 |
3–5 Times A Week | 2.27 × 107 | 1.07 × 107–4.83 × 107 | 0.000 | |
2–3 Times A Week | 8.45 × 106 | 0–0 | 0.000 | |
Once A Week | 0.14 | 0–0 | 1.000 | |
A Few Times A Month | 0.14 | 0–0 | 1.000 | |
Less Than A Few Times A Month (ref.) | - | - | - | |
Participation in weightlifting competitions | No (ref.) | - | - | - |
Yes | 2.55 | 1.24–5.24 | 0.011 | |
Participation in bodybuilding competitions | No (ref.) | - | - | - |
Yes | 4.45 × 108 | 0–0 | 0.997 | |
Having children | No (ref.) | - | - | - |
Yes | 2.28 | 1.02–5.09 | 0.045 | |
Planning to have children | No (ref.) | - | - | - |
Yes | 0.65 | 0.35–1.21 | 0.171 | |
Occupation | Other | 1.71 × 109 | 0–0 | 0.998 |
Engineers | 1.71 × 109 | 0–0 | 0.998 | |
Managers in corporations and enterprises | 17.55 | 3.91–78.76 | 0.000 | |
Coaches | 7.80 | 0.42–145.21 | 0.169 | |
Uniformed services | 7.80 | 0.42–145.21 | 0.169 | |
People running their own business | 7.80 | 2.44–24.9 | 0.001 | |
Unemployed | 5.20 | 0.69–39.08 | 0.109 | |
Civil servants | 4.68 | 0.85–25.81 | 0.076 | |
Corporate employees | 3.90 | 1.17–12.96 | 0.026 | |
Employees of small- and medium-sized enterprises | 3.90 | 1.11–13.75 | 0.034 | |
Health care workers | 1.56 | 0.26–9.26 | 0.625 | |
Athletes | 0.00 | 0–0 | 0.999 | |
Students (ref.) | - | - | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Skrzypiec-Spring, M.; Pokrywka, A.; Bombała, W.; Berezovska, D.; Rozmus, J.; Brawańska, K.; Nowicki, K.; Abu Faraj, G.; Rynkowski, M.; Szeląg, A. Illegal Use of Testosterone and Other Anabolic–Androgenic Steroids in the Population of Amateur Athletes in Wrocław, Poland—An Unfavorable Lifestyle Trend in the Population of Men of Reproductive Age. J. Clin. Med. 2024, 13, 3719. https://doi.org/10.3390/jcm13133719
Skrzypiec-Spring M, Pokrywka A, Bombała W, Berezovska D, Rozmus J, Brawańska K, Nowicki K, Abu Faraj G, Rynkowski M, Szeląg A. Illegal Use of Testosterone and Other Anabolic–Androgenic Steroids in the Population of Amateur Athletes in Wrocław, Poland—An Unfavorable Lifestyle Trend in the Population of Men of Reproductive Age. Journal of Clinical Medicine. 2024; 13(13):3719. https://doi.org/10.3390/jcm13133719
Chicago/Turabian StyleSkrzypiec-Spring, Monika, Andrzej Pokrywka, Wojciech Bombała, Daria Berezovska, Julia Rozmus, Kinga Brawańska, Konrad Nowicki, Gina Abu Faraj, Michał Rynkowski, and Adam Szeląg. 2024. "Illegal Use of Testosterone and Other Anabolic–Androgenic Steroids in the Population of Amateur Athletes in Wrocław, Poland—An Unfavorable Lifestyle Trend in the Population of Men of Reproductive Age" Journal of Clinical Medicine 13, no. 13: 3719. https://doi.org/10.3390/jcm13133719
APA StyleSkrzypiec-Spring, M., Pokrywka, A., Bombała, W., Berezovska, D., Rozmus, J., Brawańska, K., Nowicki, K., Abu Faraj, G., Rynkowski, M., & Szeląg, A. (2024). Illegal Use of Testosterone and Other Anabolic–Androgenic Steroids in the Population of Amateur Athletes in Wrocław, Poland—An Unfavorable Lifestyle Trend in the Population of Men of Reproductive Age. Journal of Clinical Medicine, 13(13), 3719. https://doi.org/10.3390/jcm13133719